A preclinical study of a candidate drug to treat opioid use disorder has shown an ability to reduce oxycodone intake and quell drug-seeking behaviour in an animal model. The drug, ADX106772, is a metabotropic glutamate 2 (mGlu2) positive allosteric modulator developed by Addex Therapeutics SA of Switzerland.
